It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction
The profiles of patients with COVID-19 have been widely studied, but little is known about differences in baseline characteristics and in outcomes between subjects with a ceiling of care assigned at hospital admission and subjects without a ceiling of care. The aim of this study is to compare, by ceiling of care, clinical features and outcomes of hospitalized subjects during four waves of COVID-19 in a metropolitan area in Catalonia.
Methods
Observational study conducted during the first (March–April 2020), second (October–November 2020), third (January–February 2021), and fourth wave (July–August 2021) of COVID-19 in five centers of Catalonia. All subjects were adults (> 18 years old) hospitalized with a proven SARS-CoV-2 infection and with therapeutic ceiling of care assessed by the attending physician at hospital admission.
Results
A total of 5813 subjects were analyzed. Subjects with a ceiling of care were mainly older (difference in median age of 20 years), with more comorbidities (Charlson index 3 points higher) and with fewer clinical signs at baseline than patients without a ceiling of care. Some features of their clinical profiles changed among waves. There were differences in treatments received during hospital admission across waves, but not between subjects with and without a ceiling of care. Subjects with a ceiling of care had a death incidence more than four times the death incidence of subjects a without a ceiling of care (risk ratio (RR) ranging from 3.5 in the first wave to almost 6 in the third and fourth). Incidence of severe pneumonia and complications for subjects with a ceiling of care was around 1.5 times the incidence in subjects without a ceiling of care.
Discussion
Analysis of hospitalized subjects with SARS-CoV-2 infection should be stratified according to therapeutic ceiling of care to avoid bias and outcome misestimation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 L’Hospitalet de Llobregat, Biostatistics Unit of the Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain (GRID:grid.417656.7); University of Barcelona, Department of Clinical Sciences, School of Medicine and Health Sciences, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
2 Bellvitge University Hospital, Department of Infectious Diseases, Barcelona, Spain (GRID:grid.411129.e) (ISNI:0000 0000 8836 0780); Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257)
3 University of Barcelona, Department of Clinical Sciences, School of Medicine and Health Sciences, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); Consorci Sanitari Integral, Department of Internal Medicine, Barcelona, Spain (GRID:grid.418284.3)
4 CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427); Consorci Sanitari Alt Penedès Garraf, Department of Internal Medicine, Barcelona, Spain (GRID:grid.413448.e)
5 Consorci Sanitari Alt Penedès Garraf, Research Area, Barcelona, Spain (GRID:grid.413448.e)
6 Viladecans Hospital, Department of Anaesthesiology, Barcelona, Spain (GRID:grid.413448.e)
7 Parc Sanitari Sant Joan de Deu, Department Infectious Diseases, Barcelona, Spain (GRID:grid.466982.7) (ISNI:0000 0004 1771 0789)
8 L’Hospitalet de Llobregat, Biostatistics Unit of the Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain (GRID:grid.417656.7)
9 Universitat Politècnica de Catalunya/Barcelonatech, Department of Statistics and Operations Research, Barcelona, Spain (GRID:grid.6835.8) (ISNI:0000 0004 1937 028X)
10 University of Barcelona, Department of Clinical Sciences, School of Medicine and Health Sciences, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247); Bellvitge University Hospital, Department of Infectious Diseases, Barcelona, Spain (GRID:grid.411129.e) (ISNI:0000 0000 8836 0780); Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
11 Bellvitge University Hospital, Department of Clinical Pharmacology, Barcelona, Spain (GRID:grid.411129.e) (ISNI:0000 0000 8836 0780); University of Barcelona, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)